Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Drug Metabolism & Disposition
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Drug Metabolism & Disposition

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit dmd on Facebook
  • Follow dmd on Twitter
  • Follow ASPET on LinkedIn
Research ArticleArticle

Modification of Paclitaxel Metabolism in a Cancer Patient by Induction of Cytochrome P450 3A4

Bernard Monsarrat, Etienne Chatelut, Isabelle Royer, Paul Alvinerie, Joelle Dubois, Annik Dezeuse, Henri Roché, Suzy Cros, Michel Wright and Pierre Canal
Drug Metabolism and Disposition March 1998, 26 (3) 229-233;
Bernard Monsarrat
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Etienne Chatelut
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Isabelle Royer
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paul Alvinerie
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joelle Dubois
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Annik Dezeuse
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Henri Roché
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Suzy Cros
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michel Wright
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pierre Canal
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

Biliary, plasma, and urinary disposition of paclitaxel and paclitaxel metabolites were determined simultaneously in a patient with percutaneous biliary drain. The complete chemical structures of the major metabolites were established by mass spectrometry and NMR spectroscopy. A nonlinear elimination model was indicated by the fact that the rate of biliary excretion of paclitaxel rose as plasma concentrations fell. Dihydroxypaclitaxel was the predominant biliary metabolite, in contrast to the barely detectable levels in two previous patients. This derivative results from hydroxylation at the C6 position of the taxane ring and at the phenyl C3′-position on the C13 side chain mediated by cytochrome P450 2C8 and 3A4, respectively. In line with this mechanism, the two other main metabolites corresponded to 6α-hydroxypaclitaxel and to the paclitaxel derivative hydroxylated in the para-position on the phenyl ring at the C3′-position of the C13. A high CYP3A4 activity in the patient is consistent with the repeated administration of methylprednisolone for 14 days before paclitaxel treatment, a compound known to induce the CYP3A isoform, and with the increased ratio of 6β-hydroxycortisol/cortisol in urine, an index of CYP3A activity. These findings emphasize the influence of pretreatment with corticoids on the disposition of paclitaxel.

Footnotes

  • Send reprint requests to: Dr. Monsarrat Bernard, Institut de Pharmacologie et de Biologie Structurale, Centre National de la Recherche Scientifique, 205 route de Narbonne, 31077 Toulouse Cedex, France.

  • This work was supported by a grant from l’Association pour la Recherche sur le Cancer and the Conseil Régional of Midi Pyrénées. Part of this research was presented previously at the 88th Annual Meeting of the American Association for Cancer Research in San Diego, CA.

  • Abbreviations used are::
    CYP3A4 and CYP2C8
    cytochrome P450 isoform 3A4 and 2C8
    AUC
    area under the concentration-time curve
    HPLC
    high performance liquid chromatography
    LC/MS-APCI
    liquid chromatography/mass spectrometry-atmospheric pressure chemical ionization mode
    • Received June 16, 1997.
    • Accepted November 25, 1997.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

 

DMD articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Drug Metabolism and Disposition
Vol. 26, Issue 3
1 Mar 1998
  • Table of Contents
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Drug Metabolism & Disposition article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Modification of Paclitaxel Metabolism in a Cancer Patient by Induction of Cytochrome P450 3A4
(Your Name) has forwarded a page to you from Drug Metabolism & Disposition
(Your Name) thought you would be interested in this article in Drug Metabolism & Disposition.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

Modification of Paclitaxel Metabolism in a Cancer Patient by Induction of Cytochrome P450 3A4

Bernard Monsarrat, Etienne Chatelut, Isabelle Royer, Paul Alvinerie, Joelle Dubois, Annik Dezeuse, Henri Roché, Suzy Cros, Michel Wright and Pierre Canal
Drug Metabolism and Disposition March 1, 1998, 26 (3) 229-233;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

Modification of Paclitaxel Metabolism in a Cancer Patient by Induction of Cytochrome P450 3A4

Bernard Monsarrat, Etienne Chatelut, Isabelle Royer, Paul Alvinerie, Joelle Dubois, Annik Dezeuse, Henri Roché, Suzy Cros, Michel Wright and Pierre Canal
Drug Metabolism and Disposition March 1, 1998, 26 (3) 229-233;
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Patient, Materials and Methods
    • Results
    • Discussion
    • Acknowledgment
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Identification of payload-containing catabolites of ADCs
  • PK Interactions of Licorice with Cytochrome P450s
  • Biotransformation of Trastuzumab and Pertuzumab
Show more Article

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About DMD
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Journal of Pharmacology and Experimental Therapeutics
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-009X (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics